<DOC>
	<DOCNO>NCT02537457</DOCNO>
	<brief_summary>The objective study establish bioequivalence rivaroxaban tablet 15 mg rivaroxaban granule formulation 15 mg , assess safety tolerability rivaroxaban 15 mg healthy adult male subject .</brief_summary>
	<brief_title>Bioequivalence Study Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Japanese healthy male subject 20 40 year age 17.6 26.4 kg / mÂ² body mass index ( BMI ) Subject incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Subject history relevant diseases vital organ , central nervous system organ , eg instable coronary heart disease , heart failure , liver failure , kidney failure , hypotension , history stroke myocardial infarction Subject know coagulation disorder ( eg von Willebrand 's disease , hemophilia ) Subject know disorder increase bleed risk ( eg periodontosis , hemorrhoid , acute gastritis , peptic ulcer ) Subject know sensitivity common cause bleeding ( eg nasal )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>